Biocon, a leading biotechnology company, proudly announces its inclusion in the S&P Global Sustainability Yearbook 2024 for the second consecutive year. This recognition is based on the S&P Global Corporate Sustainability Assessment (CSA) of both Biocon and Biocon Biologics Limited for the year 2023.
Demonstrating a commitment to sustainability, Biocon has implemented a progressive Environment, Social, and Governance (ESG) strategy aligned with stakeholder expectations and business objectives. Notably, Biocon’s S&P Global ESG score has risen to 63, a significant improvement from 52 previously, positioning the company among the Top 10 global biotechnology companies out of the 300 assessed.
Kiran Mazumdar Shaw, Chairperson of Biocon & Biocon Biologics, expressed delight, stating, “We are pleased to be recognized by S&P Global for our robust sustainable business practices.” She emphasized the company’s dedication to comprehensive ESG strategies, aligning with their philosophy of Unconditional Equity, and striving to achieve Patient Equity, People Equity, Environmental Equity, Stakeholder Equity, and Social Equity.
The S&P Global CSA, a leading corporate sustainability database, plays a crucial role in enabling companies to report key sustainability metrics and benchmark their performance against industry-specific criteria. Biocon’s score also earned them a place among global sustainability leaders for the third consecutive year in the Dow Jones Sustainability Emerging Markets Index, tracking the top 10% of the 800 largest Emerging Markets companies in the S&P Global Broad Market Index.
The company’s sustainability success is attributed to embedding these principles into its corporate culture and daily operations, facilitating the development of life-saving medicines in an environmentally and socially responsible manner. Biocon’s holistic ESG strategy has permeated throughout the organization, reflecting its dedication to responsible business practices and sustainability, aligning with the mission to make a meaningful impact on society and the environment.
Key highlights of Biocon’s 2023 S&P Global ESG scores showcase its strong performance across various dimensions:
– Environmental Dimension: Achieved an impressive score of 69, surpassing the industry mean of 12.
– Social Dimension: Attained a score of 62, significantly exceeding the mean of 24.
– Governance & Economic Dimension: Secured a score of 62, well above the mean of 30.
These scores are a testament to Biocon’s commitment to sustainability across different aspects of its operations.
In the 2023 assessment, S&P’s CSA covered 62 industries, assessing 9,400 companies, analyzing 174,000 documents, and processing 16.5 million data points. To earn a place in the prestigious Yearbook, companies must rank within the top 15% of their industry and achieve an S&P Global Sustainability Score within 30% of their industry’s top-performing company.
Biocon’s dedication to responsible business practices and sustainability has resulted in significant improvements in its ratings across various global indices, showcasing its unwavering commitment to making a positive impact on society and the environment. The company’s achievements underscore its position as a leader in the biotechnology sector, setting the standard for sustainable and ethical business practices.
Leave a comment